4.58 USD
▼-0.35-7.10%
盘后 6.50 0.00%
2026-11-20
市值
$7.94M
市盈率
—
EPS
-5.01
股息率
—
52 周区间
4.51 – 31.00
成交量
20.03K
Beta
0.32
目标价
53.50
52W 低 4.5152W 高 31.00
价格走势
公司简介
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. li...